Shanghai Pharma (601607.SH) Receives Manufacturing Approval for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets

Stock News

Feb 04

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate No.: 2026S00307) from the National Medical Products Administration (NMPA) for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, granting approval for production.

This medication is indicated for the treatment of adult patients with type 2 diabetes mellitus who are already on a combined therapy of sitagliptin and metformin extended-release tablets.

The drug was initially developed by Merck Sharp & Dohme and was first launched in the United States in 2012.

In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and market approval for this drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 8.49 million in research and development costs for this pharmaceutical product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1186652322"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186652322\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186652322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186652322","market":"us","top_or_hot":-1,"title":"Shanghai Pharma (601607.SH) Receives Manufacturing Approval for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate No.: 2026S00307) from the National Medical Products Administration (NMPA) for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, granting approval for production.</p>\n<p>This medication is indicated for the treatment of adult patients with type 2 diabetes mellitus who are already on a combined therapy of sitagliptin and metformin extended-release tablets.</p>\n<p>The drug was initially developed by Merck Sharp & Dohme and was first launched in the United States in 2012.</p>\n<p>In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and market approval for this drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 8.49 million in research and development costs for this pharmaceutical product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharma (601607.SH) Receives Manufacturing Approval for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharma (601607.SH) Receives Manufacturing Approval for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-04 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate No.: 2026S00307) from the National Medical Products Administration (NMPA) for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, granting approval for production.</p>\n<p>This medication is indicated for the treatment of adult patients with type 2 diabetes mellitus who are already on a combined therapy of sitagliptin and metformin extended-release tablets.</p>\n<p>The drug was initially developed by Merck Sharp & Dohme and was first launched in the United States in 2012.</p>\n<p>In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and market approval for this drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 8.49 million in research and development costs for this pharmaceutical product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1186652322","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186652322","pubTimestamp":1770197778,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0187":"一线龙头","BK0020":"浦东新区","BK1197":"保健护理产品经销商","02607":"上海医药","BK0209":"零售","BK0183":"MSCI概念","BK0188":"融资融券","BK0099":"上海本地重组","BK0028":"国家队","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK0184":"上海国资改革","BK0097":"医药电商"},"translate_title":"上海医药(601607.SH)西格列汀盐酸二甲双胍缓释片获生产批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently obtained a Drug Registration Certificate (Certificate No.: 2026S00307) from the National Medical Products Administration (NMPA) for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, granting approval for production.\nThis medication is indicated for the treatment of adult patients with type 2 diabetes mellitus who are already on a combined therapy of sitagliptin and metformin extended-release tablets.\nThe drug was initially developed by Merck Sharp & Dohme and was first launched in the United States in 2012.\nIn June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and market approval for this drug to the NMPA, which was subsequently accepted.\nAs of the announcement date, the company has invested approximately RMB 8.49 million in research and development costs for this pharmaceutical product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}